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Abstract:Giant cell tumor of bone (GCTB) is a locally aggressive
subarticular tumor. Having recently reported that H3.3 G34W
mutations are characteristic of this tumor type, we have now
investigated the sensitivity and speciﬁcity of the anti-histone
H3.3 G34W rabbit monoclonal antibody in a wide variety of
tumors including histologic mimics of GCTB to assess its value
as a diagnostic marker. We also determined the incidence ofH3.3
G34 mutations in primary malignant bone tumors as assessed by
genotype and H3.3 G34W immunostaining. A total of 3163
tumors were tested. Totally, 213/235 GCTB (90.6%) showed
nuclear H3.3 p.G34W immunoreactivity. This was not the case
for the rare variants, p.G34L, M, and V, which occurred most
commonly in the small bones of the hands, patella, and the axial
skeleton. If these sites were excluded from the analysis, H3.3
G34W expression was found in 97.8% of GCTB. Malignant
bone tumors initially classiﬁed as osteosarcomas were the only
other lesions (n=11) that showed G34W expression. Notably an
additional 2 previously reported osteosarcomas with a p.G34R
mutation were not immunoreactive for the antibody. A total of
11/13 of these malignant H3.3-mutant tumors exhibited an
osteoclast-rich component: when imaging was available all but
one presented at a subarticular site. We propose that subarticular
primary malignant bone sarcoma with H3.3 mutations represent
true malignant GCTB, even in the absence of a benign GCTB
component.
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G iant cell tumor of bone (GCTB) is a locally aggressiveprimary bone tumor that is characteristically sited in
the subarticular (epiphyseal/epimetaphyseal) location. The
distal femur and proximal tibia are the most common sites
but the distal radius and proximal humerus are not
uncommonly aﬀected.1 In the axial skeleton, the proximal
sacrum is the most common location but GCTB can occur
in almost any bone, including the small bones of the hands
and feet, and sesamoid bones such as the patella.2–4
Patients are most frequently aﬀected in their third and
fourth decades and there is a slight female predominance
(1.5F:1M). Reports of GCTB in the immature skeleton are
extremely rare.5 GCTB is one of the few “benign” tumors
that occasionally metastasizes to the lungs.6
In the classical clinical and radiologic settings, GCTB
does not pose a major diagnostic challenge. However, due
to the morphologic intratumoral heterogeneity, including
secondary aneurysmal bone cyst (ABC) change, extensive
infarction with associated ﬁbroblastic overgrowth and high
mitotic activity, it may be diﬃcult to reach a deﬁnitive
diagnosis particularly on small biopsies.1 The diﬀerential
diagnoses include the numerous osteoclast-rich lesions of
bone: chondroblastoma, nonossifying ﬁbroma (NOF),
primary ABC, giant cell lesions of the small bones and
jaw (giant cell granulomas), brown tumor of hyper-
parathyroidism and tenosynovial giant cell tumor invading
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bone. The greatest of these challenges involves dis-
tinguishing conventional GCTB from malignancy in a
GCTB, and from an osteoclast-rich osteosarcoma, partic-
ularly on a biopsy.7–9 Furthermore, there is no consensus
on the best treatment for malignancy in GCTB.6,8–11
Malignancy in a GCTB is characterized by areas of
high-grade sarcoma juxtaposed to a conventional
GCTB.1 The malignant component does not have a
speciﬁc phenotype: it may be osteoclast-rich and tumor
osteoid may be evident. Most cases arise de novo
(primary malignancy in GCTB) when the atypical fea-
tures are identiﬁed at presentation. Secondary malignancy
in GCTB presents on tumor recurrence of a previously
conventional GCTB, which has usually been treated with
irradiation or surgery. Malignancy in GCTB is un-
common and reported to occur as rarely as <2% to up to
9% of GCTB.7–9,12
We have recently reported the presence of a histone
H3F3A (H3.3) gene mutation involving a substitution in
glycine 34 in 96% of GCTB, the vast majority of which
are represented by p.Gly34Trp (p.G34W), although
small numbers of G34L, V, and M variants have been
detected.13,14 We also published that chondroblastoma
harbors a H3.3 p.Lys36Met (p.K36M) mutation, gen-
erally in the H3F3B gene, although occasionally in
H3.3A, in over 90% of cases. These H3.3 mutations are
mutually exclusive and appear to be rare events outside
these 2 tumor types.15,16 Importantly, the neoplastic
element of the tumor is represented by the stromal
mononuclear cells and not the osteoclasts.13
We have previously reported H3.3 p.G34 mutations
in 2% of osteosarcoma (2/103): both had a G34R
substitution13 and others have reported another 2 cases of
malignant osteoclast-rich tumors with a G34W sub-
stitution.14 In addition, H3.3 p.G34W has been
implicated in a new mosaic disorder characterized by
pheochromocytomas, paragangliomas, and GCTB.17 To
our knowledge H3.3 p.G34 mutations have not been
reported in malignancy in GCTB although theH3.3 pG34
mutations reported in conventional GCTB have been
reported in “symplastic/pseudoanaplastic GCTB of
bone”: this is a rare entity describing the presence of
scattered atypia and “smudged” cells in an otherwise
typical GCTB.18
We have already demonstrated the clinical beneﬁt of
a rabbit monoclonal histone H3F3 K36M antibody when
diagnosing chondroblastoma.19 Having an antibody for
detection of H3.3 p.G34W would also be valuable as a
diagnostic tool.
In this study we investigated sensitivity and speci-
ﬁcity of the anti-histone H3.3 G34W Rabbit monoclonal
antibody (clone RM263; RevMAb Biosciences USA, San
Francisco, CA) in a wide variety of tumors, including
histologic mimics of GCTB to assess its value as a
diagnostic marker, with a particular attention to biopsy
material. A major focus of the study involved genoty-
ping and immunostaining a series of osteosarcomas to
determine the incidence of H3.3 G34 mutations in these
primary malignant bone tumors.
MATERIALS AND METHODS
Cases of interest were identiﬁed by searching the
histopathology archives at the Royal National Orthopaedic
Hospital, UK and Basel Bone Tumour Reference Centre,
Switzerland. Samples were obtained from the Stanmore
Musculoskeletal Biobank, a satellite of the UCL/UCLH
Biobank (HTA License number 12055), which was ap-
proved by the National Research Ethics Committee
(reference 15/YH/0311). This speciﬁc study was approved
by the NREC-approved UCL/UCLH Biobank Ethical
Review Committee (reference EC17.14), and from the
Ethikkommission beider Basel (reference 274/12). The tu-
mors were classiﬁed according to the 2013 World Health
Organization classiﬁcation of soft tissue and bone tumors.20
All samples were diagnosed by specialist bone
tumor pathologists at RNOH (A.M.F., F.A., and R.T.),
and at BBTRC (D.B.) according to the current World
Health Organization classiﬁcation. Individual cases were
correlated with clinical and radiologic information where
available. Tissue sample types and numbers are listed
below. In cases where the histology and genotyping did
not match, the morphology was reevaluated independently
by all members of the RNOH pathology team and a con-
sensus reached.
All samples were ﬁxed in 10% formal saline and
processed in paraﬃn wax after which the tissue sections
were stained with hematoxylin and eosin. The standard
operating procedure for decalciﬁcation at RNOH in-
volves the use of EDTA for at least a part of the speci-
men, even if heavily calciﬁed. To accelerate the
decalciﬁcation process at least part of heavily calciﬁed
samples are decalciﬁed in nitric acid (5%).
Either full tissue sections or sections from previo-
usly constructed tissue microarrays were cut for im-
munohistochemistry, as previously described.21 In brief, tissue
microarrays in formalin-ﬁxed paraﬃn-embedded blocks were
built with a manual arrayer (Beecher Instruments, Sun Prairie,
WI). Duplicate 0.6 to 1.0mm diameter cores were taken from
each case. All biopsies were tested in full sections.
The anti-histone H3.3 G34W Rabbit monoclonal
antibody (clone RM263; RevMAb Biosciences USA)
(diluted 1:1500), and the rabbit monoclonal histone H3F3
K36M antibody (clone RM193; RevMAb Biosciences
USA) (diluted 1:400) were both kindly provided as a gift
by RevMAb Biosciences USA. Immunohistochemistry was
performed with the Leica Bond 3 fully automated im-
munohistochemistry stainer (Leica Microsystems, Milton
Keynes, UK). Leica epitope retrieval 2 solution was used
for 20 minutes. Immunohistochemical reactions were
characterized as positive when there was unequivocal
strong crisp nuclear expression and negative when ex-
pression was not detected. Control material was a GCTB
and a chondroblastoma as appropriate in which the rele-
vant mutation had been demonstrated by DNA sequenc-
ing and which revealed strong and crisp nuclear expression.
Genotyping of the H3.3 G34W, and H3.3 K36M
mutations was undertaken using a variety of techniques
including either digital polymerase chain reaction, targeted
next generation sequencing with the Ion Personal Genome
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Machine, whole genome sequencing, and whole exome
sequencing.13,14 USP6 gene rearrangement analysis was
performed using interphase ﬂuorescence in situ hybrid-
ization analysis (ZytoLight SPEC USP6 Dual Color Break
Apart Probe; Zytovision, Bremerhaven, Germany) as
previously reported.22,23
A total of 3163 cases were tested for the expression
of H3.3 G34W and included 235 GCTB from common
anatomic sites (femur, tibia, radius, ulna, ﬁbula, humerus,
pelvis, and sacrum: 206 tumors), as well as less frequent
sites (29 tumors) including vertebrae, clivus, short bones
of the hands and feet, and patella. Included in these 235
tumors was the validation group of 138 tumor samples
(see below). The age at presentation of the GCTB cohort
ranged from 13 to 76 years old (mean: 34.7 y): these oc-
curred in 128 men and 107 women (1.2M:1F ratio).
A total of 750 mimics of GCTB were also tested, in-
cluding primary ABC (n=55), chondroblastoma (all H3.3
K36M immunoreactive) (n=58), giant cell granulomas of
the jaw (n=99), cherubism with a SH3BP2 alteration
(n=3), chondromyxoid ﬁbromas (n=45), NOF (n=28),
osteoblastomas (n=27), osteosarcomas (n=385), tenosy-
novial GCT (n=46), foreign body-type giant cell reaction
(n=1), and brown tumors of hyperparathyroidism (n=3).
An additional group of 2,178 tumors tested for H3.3 G34W
occurring in bone and soft tissue, included angiosarcomas
(n=31), carcinomas (breast, prostate, renal, bowel, and
squamous) (n=519), clear cell sarcomas (n=16), chordo-
mas (n=494), conventional cartilaginous tumors (enchon-
dromas and chondrosarcomas) (n=86), extraskeletal
myxoid chondrosarcomas (n=30), ﬁbrous dysplasia
(n=56), gastrointestinal stromal tumors (n=52), Langer-
hans cell histiocytosis (n=7), leiomyosarcomas (n=83),
spindle cell lipomas (n=5), dediﬀerentiated liposarcomas
(n=13), pleomorphic liposarcomas (n=24), mesenchymal
chondrosarcomas (n=7), melanomas (n=26), myxoﬁ-
brosarcomas (n=162), malignant peripheral nerve sheath
tumor (n=285), neuroﬁbromas (n=57), phosphaturic
mesenchymal tumors (n=9), plasma cell tumors (n=8),
undiﬀerentiated pleomorphic sarcomas (n=44), solitary
ﬁbrous tumors (n=42), soft tissue chondromas (n=18),
soft tissue giant cell tumors (n=2), soft tissue osteosarco-
mas (n=10), and synovial sarcomas (n=92).
Validation of the H3.3 G34W Antibody
Genotyping identiﬁed the H3.3 p.G34W mutation
in 138 neoplasms with typical histologic features of
GCTB on a resection or curettage specimens. All except
one of these 138 tumors was immunoreactive for this
protein and none expressed the H3.3 K36M mutant
protein characteristic of chondroblastoma, nor exhibited
an USP6 rearrangement, characteristic of primary ABC.
Furthermore, 50 cases of GCTB which exhibited strong
nuclear expression for H3.3 G34W failed to reveal a
K36M substitution by genotyping.
Imaging
Imaging was reviewed when there was a discrepancy
between the diagnosis of a GCTB and the absence of
immunoreactivity for H3.3 G34W, and in cases diagnosed
before the age of 18 years.
RESULTS
Of the entire set of 235 GCTB analyzed 213 (90.6%)
revealed strong nuclear expression for H3.3 G34W (Fig. 1).
Of the remaining 22 negative samples, 6 harbored another
G34 substitution (2x p.G34V, 3x p.G34L, and 1x p.G34M):
genotyping gave a noninformative result in 3 cases, and
1 case with a DNA sequenced-proven G34W mutation was
negative on immunohistochemistry (Table 1). The out-
standing 12 cases (5.1% of the total group of 235) were
found to be wild-type for H3F3A G34 and negative for
both the characteristic USP6 gene rearrangement found in
ABC and H3.3 K36M substitution seen in chondro-
blastoma. Hence, when the noninformative cases are
excluded, 94.8% of GCTB harbor a H3.3 G34 mutation.
We next classiﬁed the 235 GCTB on the basis of
anatomic site (Table 1): 184 tumors occurred in long ap-
pendicular bones (femur, tibia, radius, ulna, humerus, and
ﬁbula) of which 174 (94.6%) expressed H3.3 G34W. Of the
10 negative cases, 4 revealed a diﬀerent G34 substitution
(x2 p.G34V, x1 p.G34L and x1 p.G34M). When excluding
the 2 cases that were noninformative on genotyping, only
2.2% (4 cases) of the 235 GCTB of the long appendicular
bones were wild-type for G34. In addition, all GCTB from
the sacrum (n=9), and the pelvis (ilium, ischium) (n=13)
were immunoreactive for G34W. In contrast 60% (n=3/
5) and 58.3% (n=14/24) of GCTB of the axial skeleton
(excluding sacrum and pelvis), and the small bones of the
hands and feet and patella, respectively were found to be
wild-type for H3.3 G34 (Table 1).
The H3.3 G34W mutant tumors exhibited strong
and diﬀuse nuclear immunoreactivity in the vast majority
of cases (Fig. 1). In 3 cases, the immunostaining was
weaker than generally observed, and was present in a
patchy distribution, largely seen at the periphery of the
tissue section, but still was unequivocally positive. On
investigation, these 3 cases were found to have been
subjected to harsh acid-based decalciﬁcation, and notably
they were also noninformative on genotyping.
Mimics of GCTB
Study of the mimics of GCTB revealed 3 tumors
that expressed H3.3 G34W. mutant tumors On review the
diagnoses were altered to GCTB. One was originally in-
terpreted as an unusual osteoblastoma of the rib and 2
cases as ABC. The latter were sited in the distal femur and
exhibited secondary ABC-like change, and a USP6
translocation was not detected by ﬂuorescence in situ
hybridization.
Malignant Bone Tumors With H3.3 G34
Mutations
Of the 2928 non-GCTB tumors the only subtype that
revealed H3.3 G34W immunoreactivity was osteosarcoma.
Of the 385 osteosarcomas of the skeleton 11 (2.85%)
revealed G34W immunoreactivity (Fig. 2 and Table 2). Of
these one fulﬁlled the WHO criteria of primary malignant
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GCTB with the malignant component being a low-grade
central OS which tested negative for MDM2 gene ampliﬁ-
cation (Fig. 3). Nine of the remaining 10 OS had an
osteoclast-rich component, and 1 was a chondroblastic
osteosarcoma. All 9 cases for which macroscopic and/or
radiologic information was available, were sited in the
subarticular area. Of the 385 cases, 237 were also genotyped
(103 previously performed13,14) and the absence of G34W
substitution supported the lack of immunoreactivity in the
majority of osteosarcomas. The genotyping also revealed a
H3.3 G34 alteration in 2 cases (both with H3.3 G34R
mutations—one in H3F3A and 1 in H3F3B, both reported
previously13) but no other G34 substitutions. One of these
was a subarticular osteoclast-rich osteosarcoma. Combining
the results, 13/385 (3.37%) primary malignant bone tumors
classified as either osteosarcoma or malignant GCTB
harbored a p.G34 alteration. The p.G34W mutation was 4
times more common than the other G34 substitutions.
None of the primary tumors had been treated with
radiotherapy. Table 2 provides details of these 13 cases.
The average age at presentation for malignant tumors
with H3.3 mutations was 34 (range: 19 to 64): 4M:9F.
H3.3 G34W Immunohistochemistry on Biopsy
Material
To determine the value of the H3.3 G34W im-
munohistochemistry for diagnosing GCTB on biopsy
specimens, we analyzed 94 consecutive osteoclast-rich
biopsies samples over an 18-month period. The resection/
curettage specimens related to these biopsies were also
tested for G34W immunoreactivity (Table 3). A deﬁnitive
diagnosis of GCTB on biopsy could have been increased
by 5 cases with the aid of immunohistochemistry. Of the
59 cases where the diagnosis of GCTB was provided on
resection/curettage, H3.3 G34W was expressed in 57
(96.6%).
Imaging
Five cases in our cohort presented in patients 15
years old or younger: the youngest presented at 13. The
FIGURE 1. Photomicrographs (A and B) and radiographs (C) of a GCTB with extensive secondary aneurysmal bone cyst change,
in areas indistinguishable from a primary aneurysmal bone cyst. H3.3 G34W is diffusely expressed by the stromal cells. D and E
represent photomicrographs, of a different case (biopsy sample) showing a small isolated fragment of an osteoclast-rich lesion
within blood clot. Strong H3.3 G34W (E) nuclei expression confirms the suspicion of a GCTB. The osteoclasts are negative for H3.3
G34W expression.
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growth plates were open in 2 patients: one 14-year-old girl
(tumor in the distal radius, adjacent growth plates open)
and the other a 15-year-old boy (right cuboid tumor,
distal tibial, and ﬁbular growth plates open). The other
patients had closed growth plates. The malignant tumors
harboring a H3.3 mutation were usually accompanied by
aggressive radiologic features which were not compatible
with a diagnosis of conventional GCTB.
DISCUSSION
This study demonstrates that the anti-histone H3.3
G34W Rabbit monoclonal antibody (clone RM263) is
highly speciﬁc and sensitive for tumors harboring this
mutation and is a powerful marker for GCTB, sig-
niﬁcantly improving the diagnostic accuracy in biopsy
specimens. H3.3 G34W expression is seen exclusively in
the mononuclear cell population conﬁrming our previous
ﬁnding by genotyping that the neoplastic cell population
is represented by the mononuclear cells and not the
osteoclast-like giant cells.
The sensitivity of the antibody for the mutant pro-
tein was veriﬁed by testing 138 GCTB previously geno-
typed for the H3.3 G34W substitution: only 1 case (1/138)
failed to demonstrate immunoreactivity which is likely to
be explained by tissue ﬁxation and decalciﬁcation, high-
lighting the importance of establishing procedures for
tissue handling. The speciﬁcity of the antibody for the
mutation was demonstrated by absence of H3.3 G34W
expression in the cases proven to harbor aH3.3 G34L, M,
and V mutations in GCTB, and H3.3 G34R in 2 primary
malignant bone tumors. Furthermore, >2500 tumors
other than GCTB were not found to be immunoreactive
for this antibody including several subtypes previously
shown to be wild-type for H3.3 G34 by next generation
sequencing (ie, chondroblastomas, chondrosarcoma,
osteoblastomas, NOF ABC, and chordomas).14 Having
established the quality of this histone G34W antibody, we
have demonstrated that it is immunoreactive for 90.6% of
235 GCTB, conﬁrming the sensitivity we previously re-
ported by genotyping.14 It is noteworthy that the rare
H3.3 variants including G34L, M, and V occurred most
commonly in the small bones of the hands and feet,
patella and the axial skeleton, and if these anatomic sites
were excluded from the analysis, the G34W mutation is
found in 97.8% of GCT. The absence of H3.3 G34 mu-
tation in GCTB may be explained by a diﬀerent genetic
alteration. Alternatively, they may represent solid var-
iants of an ABC without a USP6 gene rearrangement.
GCTB have rarely been reported in the immature
skeleton: of the 235 cases in our study, 13 years of age was
the earliest age at presentation and there was a total of 13
(5.5%) patients presenting at 18 years of age or younger.
This number is slightly lower than that reported recently
by Al-Ibraheemi et al.5 However, the age of presentation
seems less important than skeletal maturity and in only
2 individuals in our cohort were the physes still open at
presentation. GCTB at a metaphyseal site in patients with
open physes is well-documented,24 and is exempliﬁed in
1 case.
TABLE 1. Giant Cell Tumors of Bone
Total Number of
Tumors
Negative for H3.3 G34W
IHC
Other G34 Substitutions
Detected
Noninformative on
Genetics
Appendicular skeleton 221 20 6 3
Femur 71 3 1 G34L and 1 G34M 1
Fibula 12 1 — —
Humerus 13 1 1 G34V
Pelvis 13 0 — —
Radius 29 2 1 G34V
Tibia 49 3 — 1
Ulna 10 0 — —
Patella 3 1 — —
Phalanx hand 6 2 — —
Metacarpal 4 1 1 G34L —
Metatarsal 2 1 — —
Cuneiform 4 4 1 G34L —
Cuboid 1 0 — —
Navicular 1 0 — —
Talus 3 1 — —
Axial skeleton 14 2 — 1
Vertebra 2 2* — 1
Clivus 2 0 — —
Rib 1 0 — —
Sacrum 9 0 — —
Grand total 235 22 6 4
Group break-down
Total long bones 197 10 4 2
Total hands/feet/
patella
24 10 2 0
*One case was negative for H3.3 G34W IHC but had a G34W mutation detected.
IHC indicates immunohistochemistry.
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In addition to the 95% of conventional GCTB in
which a H3.3 G34 mutation was detected we also iden-
tiﬁed 13 primary malignant bone tumors harboring a G34
mutation. Eleven of those harbored a G34W mutation,
and 2 had a G34R alteration (Table 2). The average age at
presentation for benign and malignant tumors with a
H3.3 G34 mutation was not dissimilar and the dis-
tinguishing feature between these tumor types was that
the immunoreactive mononuclear tumor cells in the ma-
lignant tumors displayed signiﬁcant cytologic atypia, not
FIGURE 2. Photomicrographs of a malignant GCTB (M-07: initially classified as osteoclast-rich osteosarcoma) of the distal tibia
showing morphologic variation including areas composed of epithelioid cells arranged in cords (A–C), osteoid deposition (B and
C), tumor necrosis (C), and spindle cells with moderate nuclear atypia and numerous interspersed osteoclasts (D–F). Diffuse
expression of H3.3 G34W is seen in the stromal cells (F).
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seen in conventional GCTB. Using the criteria of the
current WHO classiﬁcation, 11 of these tumors would
be classiﬁed as osteosarcoma, 1 as a pleomorphic un-
diﬀerentiated sarcoma of bone, and 1 as malignancy in a
GCTB. However, it was remarkable that osteoclast-rich
areas were observed in all but 1 of these 13 cases and that
where imaging and or macroscopic images (9/11) were
available for review, all were sited in the subarticular
region. The one case in which an osteoclast-rich compo-
nent was not detected despite extensive sampling was
sited in the diaphyseal region and presented in a patient
with Hardcastle syndrome, characterized by diaphyseal
medullary stenosis (sclerosis) with bone malignancy
(malignant ﬁbrous histiocytoma), a germline disorder
revealing structural alterations in the gene encoding
methylthioadenosine phosphorylase.25
There was only one tumor which revealed histologic
features of a typical GCTB in addition to a frankly ma-
lignant element in the tumor. In both components, the
mononuclear cell population was immunoreactive for the
TABLE 2. Malignant Bone Tumors With G34 Alterations
Case
Code
Osteoclast-
rich (GCT-
like
Component)
Osteosarcomatous
(Bone-forming)
Diﬀerentiation Initial Diagnosis
Radiology
Review /
Macroscopy
Review Site
G34W
IHC
H3F3
Mutation
Analysis Follow-up When Available
M01 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Femur,
distal, left
Negative G34R/A DOD 1 y after diagnosis
M02 Absent Absent Pleomorphic
sarcoma
associated with
Hardcastle
syndrome (MTAP
alteration)
Diaphyseal
extending
into soft
tissue
Femur,
shaft, left
Negative G34R/B DOD 2mo after diagnosis
M03 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Metatarsal,
1st, left
Positive G34W/A Recurrence 9 y after
presentation. Alive with no
residual disease (8 y after
the last recurrence).
Treated with below knee
amputation.
M04 Present Present Osteosarcoma,
osteoclast-rich
Primary
tumor
excised in
1994,
imaging
unavailable
Tibia, dstal Positive G34W/A Metastasis to the spine. Alive
with disease
M05 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Tibia, right,
proximal
Positive G34W/A Alive with no evidence of
disase (11 y follow-up).
M06 Present Present Osteosarcoma,
osteoclast-rich
No imaging
available
Femur,
right,
proximal
Positive G34W/A DOD 4y after diagnosis
M07 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Tibia, rigth,
distal
Positive G34W/A DOD 1y after diagnosis
M08 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Tibia, left,
proximal
Positive G34W/A Lung metastasis at diagnosis,
lost in follow-up
M09 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Tibia, left,
proximal
Positive,
weak,
negative
on biopsy
G34W/A Alive with no evidence of
disease (5 y follow-up)
M10 Present Present Malignant GCTB:
giant cell tumor
with low-grade
osteosarcomatous
transformation
Subarticular Femur,
distal
Positive G34W/A Alive with no evidence of
disease (1 yfollow-up)
M11 Present Present Osteosarcoma,
osteoclast-rich
Subarticular Fibula,
right,
proximal
Positive G34W/A No follow-up information
M12 Absent Present Osteosarcoma,
chondroblastic
Subarticular Tibia,
proximal,
left
Positive G34W/A No follow-up information
M13 Present Present Unusual high-grade
sarcoma with
osteosarcomatous
and epithelial
diﬀerentiation
Subarticular Tibria,
proximal,
right
Positive G34W/A DOD 8moafter diagnosis
DOD indicates Date of Death; IHC, immunohistochemistry; MTAP, methylthioadenosine phosphorylase.
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anti-histone antibody. In the other 11 tumors, the stromal
component revealed unequivocal malignant morphology
in the mononuclear cells throughout the lesion. The single
case that fulﬁlled the WHO criteria for malignancy in
GCTB was also noteworthy on account of the malignant
component displaying a low-grade ﬁbroblastic bone-
forming neoplasm reminiscent of a low-grade central
osteosarcoma, a histologic variant in malignant GCTB
not reported previously. The ﬁnding of the H3.3 mutation
in the stromal component of both the benign and malig-
nant components argues for transformation of the tumor
presumably brought about by acquisition of additional
genetic alterations, as yet undeﬁned; this also supports the
concept that this the H3.3 mutation is a driver mutation.
Although the numbers of primary malignant bone
tumors with H3.3 mutations in our study is small, there is
clear variation in the clinical behavior within the group
with the majority behaving as high-grade bone tumors.
The disease behaved aggressively in 6/10 “malignant
GCTB” cases following presentation but in 3 cases the
disease has not progressed and in 1 case the patient has
lived with metastatic disease to the spine for more than 10
years. The clinical course of the disease was not known in
2 patients as they were lost to follow-up.
Our ﬁndings beg the questions as how best to clas-
sify primary malignant bone tumors with H3.3 G34
mutations, and most importantly how best to treat the
disease. To address the ﬁrst question we propose that the
lack of a benign GCTB component in these tumors could
be considered analogous to a dediﬀerentiated chon-
drosarcoma in which the cartilaginous component is not
identiﬁed, a ﬁnding that is explained by over-growth by
the more aggressive elements of the tumor. Hence, we
propose that a primary malignant bone tumor when
presenting in a subarticular site with a H3.3 G34 muta-
tion is classiﬁed as malignancy in GCTB.
To address the issue of how best to treat malignant
tumors with H3.3 G34 mutations, we propose that
management is based on the histologic grade of the tumor
and that high grade lesions are treated with standard of
FIGURE 3. A and B, Resection specimen and corresponding coronal T1 MRI scan showing a lytic hemorrhagic lesion in the
subarticular area of the distal femur with a surrounding low signal (sclerotic) component at the proximal aspect of the lesion.
Photomicrographs of the subarticular component shows a conventional GCTB with diffuse H3.3 G34W expression (inset) (C). The
proximal component comprises a bone-forming tumor with a spindle cell stroma showing a permeative growth pattern (D and E)
(H3.3 G34W expression shown on inset D) case M10.
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care neoadjuvant chemotherapy given for osteosarcoma.
This would be in line with how any high-grade primary
bone sarcoma is treated, even those with very little or no
osteoid deposition such as telangiectatic osteosarcoma
and the rare primary ﬁbrosarcoma of bone. If this were
done, gathering data from multiple centers could poten-
tially identify in a relatively short period how this genet-
ically characterized tumor responds to chemotherapy.
Furthermore, with more widespread epi/genomic analysis
it is likely that additional epi/genetic events that account
for their malignant transformation will be identiﬁed and
used as part of the diagnostic and prognostic armory.
In summary, our ﬁndings provide strong evidence that
the anti-histone G34W antibody is a valuable tool for
supporting a diagnosis of GCTB and distinguishing GCTB
from its mimics. The limitation of this antibody is that a
small number of GCTB harbor a G34 mutation, other than
G34W that cannot be detected. Importantly, the same G34
mutations occur in a small number of primary malignant
bone tumors. Finally, the frequent association of the H3.3
G34 mutation with the presence of osteoclasts implies that
this mutant protein plays an important role in bone biology.
Understanding how the epi/genetic alterations in H3.3 are
involved in the regulation of osteoclast recruitment would
shed light on the bone cell biology in health and disease.
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